227 related articles for article (PubMed ID: 35565386)
1.
Cansouline X; Lipan B; Sizaret D; Tallet A; Vandier C; Carmier D; Legras A
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565386
[TBL] [Abstract][Full Text] [Related]
2. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
Zhai H; Zhong W; Yang X; Wu YL
Transl Lung Cancer Res; 2015 Feb; 4(1):82-93. PubMed ID: 25806348
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
Cheng H; Li XJ; Wang XJ; Chen ZW; Wang RQ; Zhong HC; Wu TC; Cao QD
Lung Cancer; 2019 Nov; 137():7-13. PubMed ID: 31520922
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients.
Chen RL; Sun LL; Cao Y; Chen HR; Zhou JX; Gu CY; Zhang Y; Wang SY; Hou W; Lin LZ
Front Oncol; 2021; 11():629394. PubMed ID: 33912453
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Adjuvant Setting for Patients with Resected Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer: A Meta-Analysis with 11 Trials.
Yin Q; Xun X; Yang G; Cui H; Liu H
Oncol Res Treat; 2021; 44(6):344-353. PubMed ID: 33951671
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
Spaans JN; Goss GD
Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
[TBL] [Abstract][Full Text] [Related]
9. The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis.
Lin C; Hu F; Chu H; Ren P; Ma S; Wang J; Bai J; Han X; Ma S
Thorac Cancer; 2021 Apr; 12(7):1084-1095. PubMed ID: 33660941
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
[TBL] [Abstract][Full Text] [Related]
11. Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC.
Brazel D; Nagasaka M
Lung Cancer (Auckl); 2022; 13():47-52. PubMed ID: 35615402
[TBL] [Abstract][Full Text] [Related]
12. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
[TBL] [Abstract][Full Text] [Related]
13. ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer.
Ortega-Franco A; Rafee S
Oncol Ther; 2022 Jun; 10(1):13-22. PubMed ID: 35294773
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives.
Kris MG; Mitsudomi T; Peters S
Transl Lung Cancer Res; 2023 Apr; 12(4):824-836. PubMed ID: 37197636
[TBL] [Abstract][Full Text] [Related]
15. Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned.
Belluomini L; Riva ST; Simbolo M; Nocini R; Trestini I; Avancini A; Tregnago D; Ferrara MG; Caldart A; Dodi A; Caliò A; Bria E; Scarpa A; Milella M; Menis J; Pilotto S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685665
[No Abstract] [Full Text] [Related]
16. EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials.
Wu JX; He Q; Ye F; Zhou QX; Chen HJ; Sun L; Wu H
Onco Targets Ther; 2018; 11():6803-6810. PubMed ID: 30349313
[TBL] [Abstract][Full Text] [Related]
17. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
Wu YL; John T; Grohe C; Majem M; Goldman JW; Kim SW; Kato T; Laktionov K; Vu HV; Wang Z; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Atasoy A; Herbst RS; Tsuboi M
J Thorac Oncol; 2022 Mar; 17(3):423-433. PubMed ID: 34740861
[TBL] [Abstract][Full Text] [Related]
18. Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer.
Sotelo MJ; Luis García J; Torres-Mattos C; Milián H; Carracedo C; González-Ruiz MÁ; Mielgo-Rubio X; Trujillo-Reyes JC; Couñago F
World J Clin Oncol; 2021 Oct; 12(10):912-925. PubMed ID: 34733613
[TBL] [Abstract][Full Text] [Related]
19. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
Walia M; Singhal MK; Kamle MS
Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
[TBL] [Abstract][Full Text] [Related]
20. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
